Case Report: Limb-sparing neoadjuvant PD-1 blockade with tumor-informed ctDNA monitoring in advanced cutaneous adnexal carcinoma of the palm

Primary adnexal carcinomas are rare, heterogeneous malignancies with limited evidence guiding the management of locally advanced disease, including the use of checkpoint inhibition. We report a 67-year-old man with a poorly differentiated cutaneous adnexal carcinoma, not otherwise specified (NOS), of the palm who received off-label neoadjuvant cemiplimab since upfront surgical resection would result in significant functional morbidity. After approximately 8 months of therapy, there was clinical and radiographic response as confirmed with tumor reduction from 5.2 x 3.8 cm to 2.3 x 1.2 cm. Serial tumor-informed ctDNA measurements initially fell but then rose despite continued radiographic improvement. This led us to proceed with surgery, as the molecular data suggested we had likely achieved our maximum benefit. The surgery was an index ray amputation rather than the more extensive hand amputation that had been initially planned. Pathology revealed residual disease with multifocal lymphovascular invasion and a focally positive deep microscopic margin. Post-operation ctDNA became undetectable, and subsequent MRI showed no evidence of disease. However, long-term oncologic control after less extensive surgery with a microscopically positive margin remains unknown. This case highlights the potential utility of longitudinal ctDNA monitoring in guiding individualized management of rare malignancies. Neoadjuvant PD-1 blockade and use of ctDNA to inform timing of surgery in this setting remain investigational.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.2011971
Primary Topic
Cancer and Skin Lesions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Limb-sparing neoadjuvant PD-1 blockade with tumor-informed ctDNA monitoring in advanced cutaneous adnexal carcinoma of the palm

Joanna Amy Kolodney, Zeriel Y. Wong, Christine Barrett, Elizabeth Anne Martin et al.
4 links
Frontiers in Oncology
Cancer and Skin Lesions
article

Case Report: Limb-sparing neoadjuvant PD-1 blockade with tumor-informed ctDNA monitoring in advanced cutaneous adnexal carcinoma of the palm

Joanna Amy Kolodney, Zeriel Y. Wong, Christine Barrett, Elizabeth Anne Martin, Grant R. McChesney, Natalie Wonsettler
article en

Abstract

Primary adnexal carcinomas are rare, heterogeneous malignancies with limited evidence guiding the management of locally advanced disease, including the use of checkpoint inhibition. We report a 67-year-old man with a poorly differentiated cutaneous adnexal carcinoma, not otherwise specified (NOS), of the palm who received off-label neoadjuvant cemiplimab since upfront surgical resection would result in significant functional morbidity. After approximately 8 months of therapy, there was clinical and radiographic response as confirmed with tumor reduction from 5.2 x 3.8 cm to 2.3 x 1.2 cm. Serial tumor-informed ctDNA measurements initially fell but then rose despite continued radiographic improvement. This led us to proceed with surgery, as the molecular data suggested we had likely achieved our maximum benefit. The surgery was an index ray amputation rather than the more extensive hand amputation that had been initially planned. Pathology revealed residual disease with multifocal lymphovascular invasion and a focally positive deep microscopic margin. Post-operation ctDNA became undetectable, and subsequent MRI showed no evidence of disease. However, long-term oncologic control after less extensive surgery with a microscopically positive margin remains unknown. This case highlights the potential utility of longitudinal ctDNA monitoring in guiding individualized management of rare malignancies. Neoadjuvant PD-1 blockade and use of ctDNA to inform timing of surgery in this setting remain investigational.

Frontiers in OncologyVol. 16
West Virginia University (US), West Virginia University Hospitals (US)
Good health and well-being
Cancer and Skin Lesions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon